Pre‐treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer

Pre‐treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer 1INTRODUCTIONLung cancer is a major cause for cancer‐related death globally. Although small cell lung cancer (SCLC) accounts for only 15% of all lung cancers, it is a rapidly progressive and often fatal form of lung cancer. Traditionally, the Veterans Administration Lung Cancer Study Group staging system was used to categorize SCLC into two stages; limited stage (LS), defined as any tumor that can be encompassed within one radiation field or is limited to a single hemithorax, while extensive stage (ES) is defined as any disease extending beyond the extent of LS. Cure in SCLC is possible only in a small proportion of patients with median survival in LS ranging from 16 to 24 months. In comparison, patients with ES‐SCLC, the survival rate is much poorer and is in the order of 6–12 months with palliative chemotherapy (CT). There has been little advancement in new therapies for this group of patients.Currently, there are no well‐established biomarkers available in SCLC that could be used as a surrogate marker to determine the likelihood of survival outcome and treatment response to potential life‐extending therapies in SCLC. High serum lactate dehydrogenase (s‐LDH) has in the past been shown in other studies to confer prognostic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Loading next page...
 
/lp/wiley/pre-treatment-serum-lactate-dehydrogenase-as-a-biomarker-in-small-cell-w9w6U0LkNx
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12674
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONLung cancer is a major cause for cancer‐related death globally. Although small cell lung cancer (SCLC) accounts for only 15% of all lung cancers, it is a rapidly progressive and often fatal form of lung cancer. Traditionally, the Veterans Administration Lung Cancer Study Group staging system was used to categorize SCLC into two stages; limited stage (LS), defined as any tumor that can be encompassed within one radiation field or is limited to a single hemithorax, while extensive stage (ES) is defined as any disease extending beyond the extent of LS. Cure in SCLC is possible only in a small proportion of patients with median survival in LS ranging from 16 to 24 months. In comparison, patients with ES‐SCLC, the survival rate is much poorer and is in the order of 6–12 months with palliative chemotherapy (CT). There has been little advancement in new therapies for this group of patients.Currently, there are no well‐established biomarkers available in SCLC that could be used as a surrogate marker to determine the likelihood of survival outcome and treatment response to potential life‐extending therapies in SCLC. High serum lactate dehydrogenase (s‐LDH) has in the past been shown in other studies to confer prognostic

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial